News

Article

Lonza Expands Florida Solid-Dose Facility

The expansion of Lonza’s Tampa site includes development and manufacturing capabilities for oral solid-dose drugs.

Lonza announced the completion of a $15-million multi-phase expansion of its oral solid-dose (OSD) development and manufacturing capabilities and capacity at its Tampa, FL site in a July 9, 2019 press release. The expansion will enable the Tampa site to provide more integrated services for customers across early-stage product development, clinical trial material manufacture, and commercialization of innovative drug products. The Tampa site is part of Lonza’s global network for the design, development, and manufacturing of drug substances and intermediates; particle engineering/bioavailability enhancement; and drug products for oral and inhaled applications.

As part of the multi-year investment, the site added a product development and quality control laboratory area with 13 processing suites. Two new packaging suites can support commercial packaging, including low-humidity environments and serialization for complete tracking and tracing of commercial products. Lonza also added new manufacturing suites and dedicated sampling and dispensing areas capable of handling highly potent compounds.

In addition, Lonza expanded and renovated the cGMP manufacturing cleanroom facility, as well as completely renovating 25,000 ftof the existing cGMP OSD manufacturing cleanroom facility.

The expansion included encapsulation and micro-dosing capabilities for Xcelodose Precision Powder Micro-Dosing Technology, Glatt GPCG-10 fluid bed processing, and Harro Hoefliger Modu-C capsule filling.

“This expansion at our Tampa site adds concept-to-commercial capacity for the US market. We continue to invest heavily in our site network to ensure that flexible, phase-appropriate and integrated capabilities are in place to meet the needs of today’s pharma and biotech innovator companies,” said Anthony Macci, senior vice-president of Global Operations, Chemical Division, Lonza Pharma & Biotech, in the press release. 

Source: Lonza

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content